5-甲酰基尿嘧啶 | 1195-08-0

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-甲酰基尿嘧啶
• 中文别名: 5-甲酰基脲嘧啶；尿嘧啶-5-甲醛；2,4-二氧代-1,2,3,4-四氢嘧啶-5-甲醛
• 英文名称: 2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde
• 英文别名: 5-formyluracil；uracil-5-carboxaldehyde；2,4-dioxo-5(1H,3H)-pyrimidinecarbaldehyde；2,4-dioxo-1H-pyrimidine-5-carbaldehyde
• CAS: 1195-08-0
• 化学式: C₅H₄N₂O₃
• mdl: MFCD00192185
• 分子量: 140.098
• InChiKey: OHAMXGZMZZWRCA-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C (dec.) (lit.)
• 密度：
  1.567±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933599090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  常温、避光、存于通风干燥处。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 5-Formyluracil
CAS-No. : 1195-08-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Safety data sheet available on request.
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C5H4N2O3
Molecular Weight : 140,1 g/mol
Component Concentration
5-Formyluracil
CAS-No. 1195-08-0 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: > 300 °C - dec.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

5-甲酰基尿嘧啶是一种5-取代尿嘧啶核苷衍生物，已探索其作为抗病毒药物和肿瘤治疗的潜在应用。

反应信息

• 作为反应物：
  描述：

  5-甲酰基尿嘧啶 在 哌啶 、 吡啶 、 N-溴代丁二酰亚胺(NBS) 、 sodium methylate 、 potassium acetate 、 六甲基二硅氮烷 作用下， 以 甲醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 35.0h， 生成 溴夫定
  参考文献：
  名称：

  尿嘧啶的5-卤代ovinyl衍生物的合成及其向2'-脱氧核糖核苷的转化

  摘要：

  在哌啶存在下用丙二酸处理5-甲酰尿嘧啶，得到（E）-5-（2-羧基乙烯基）尿嘧啶，与适当的N-卤代琥珀酰亚胺反应后，得到（E）-5-（2-溴乙烯基）尿嘧啶。 ，（E）-5-（2-氯乙烯基）尿嘧啶和（E）-5-（2-碘乙烯基）尿嘧啶。最后提到的化合物也是通过氯化碘对5-乙烯基尿嘧啶的作用而获得的。用溴处理5-（1-氯丙炔基）尿嘧啶得到5（2-溴-1-氯乙烯基）尿嘧啶，其与甲醇钠反应得到5-溴乙炔基尿嘧啶。（E）-5-（2-溴乙烯基）-尿嘧啶转化为三甲基甲硅烷基衍生物，与2-脱氧-3,5-二-O-（p（-甲苯甲酰基）-α- D-赤-五呋喃糖酰氯，得到被保护的脱氧核糖核苷的α-和β-异头物。用甲醇钠除去对甲苯甲酰基保护基，得到（E）-5-（2-溴乙烯基）-1-（2-脱氧-α- D-赤型-戊呋喃糖基）尿嘧啶和（E）-5-（2-溴夫酰基）-2'-脱氧尿苷。一系列类似的反应，得到（Ë）-5-（2-碘乙

  DOI：

  10.1039/p19810001665
• 作为产物：
  描述：

  尿嘧啶 在 盐酸 、 sodium hydroxide 作用下， 以 氯仿 、 水 为溶剂， 生成 5-甲酰基尿嘧啶
  参考文献：
  名称：

  Pyrimidinedione, pyrimidinetrione, triazinedione and

  摘要：

  化合物的化学式I：##STR1##其中R.sup.5是从式(a)、(b)、(c)和(d)中选择的基团：##STR2##以及其药用可接受的盐和N-氧化物，是用于治疗涉及直接或间接阻塞下尿道的疾病，如良性前列腺增生的α1-肾上腺素受体拮抗剂。

  公开号：

  US05859014A1
• 作为试剂：
  描述：

  1,1'-Trimethylen-biscytosin 在 5-甲酰基尿嘧啶 作用下， 以 水 、 乙腈 为溶剂， 生成 hexahydro-1H-3a,5,8,9a-tetraazacyclohepta[def]biphenylene-4,6,7,9(5H,8H)-tetraone
  参考文献：
  名称：

  氧化产生的病变作为内部嘧啶二聚体在DNA中的光敏剂。

  摘要：

  在这项工作中，注意力集中在由含有DNA发色团的病变（即5-甲酰尿嘧啶）引发的UVA光敏反应上。这是一个主要的氧化产生的病变，在UVB-UVA区域表现出增强的光吸收。结合光化学和光生物学技术的机理研究表明，对5-甲酰尿嘧啶进行辐照会导致三重激发态，从而能够通过DNA敏化DNA中环丁烷嘧啶二聚体的形成。三重态-三重态能量传递。这首次证明了氧化产生的DNA损伤可以作为一种内在的敏化剂起作用，并导致具有光致癌性的太阳光谱的有效部分得到了重要的扩展。总体而言，这提出了5-甲酰尿嘧啶病变的光致突变性加剧的问题。

  DOI：

  10.1021/acschembio.7b01097

文献信息

• [EN] 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE 3,4-SUBSTITUÉE CONVENANT COMME INHIBITEURS DE LA RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009140769A1

  公开（公告）日：2009-11-26

  The present invention relates to 3,4-substituted piperidinyl - based renin inhibitor compounds bearing at 4-position lsoqumolone and having the Formula (I) : The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.

  本发明涉及具有4-位lsoqumolone的3,4-取代哌啶基肾素抑制剂化合物，其化学式为（I）：该发明还涉及含有上述化合物的药物组合物，以及它们在治疗心血管事件和肾功能不全中的用途。
• New Metal-Free Route towards Imidazole-Substituted Uridine
  作者：Henri-Philippe Mattelaer、Anne-Sophie Van Hool、Flip de Jong、Mark Van der Auweraer、Luc Van Meervelt、Wim Dehaen、Piet Herdewijn

  DOI：10.1002/ejoc.202000563

  日期：2020.7.15

  Leusen imidazole synthesis and regioselectively introduced on ribose to obtain the desired nucleoside in a 5 step synthesis (total yield 55%). The 5‐imidazolyl moiety leads to improved fluorescence properties. The only side‐product formed was characterized by 2D‐NMR and X‐ray crystallography and could be suppressed during synthesis in favor of the desired product.

  具有双（杂）芳基核碱基的核苷作为抗病毒药物和分子探针具有独特的潜在应用。从预功能化的结构单元合成这些核苷需要过渡金属催化，并且需要使用核碱基保护基团，导致合成过程昂贵且繁琐。在此，我们报道，5-咪唑基-尿嘧啶可以通过可扩展的 Van Leusen 咪唑合成获得，并区域选择性地引入核糖上，通过 5 步合成获得所需的核苷（总产率 55%）。 5-咪唑基部分可改善荧光特性。所形成的唯一副产物通过 2D-NMR 和 X 射线晶体学进行了表征，并且可以在合成过程中被抑制，有利于所需产物。
• [EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009070869A1

  公开（公告）日：2009-06-11

  The present invention relates to piperidinyl-based renin inhibitor compounds having the formula containing amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及含有氨基末端基团的哌啶基肾素抑制剂化合物，以及它们在治疗心血管事件和肾功能不全方面的用途。
• [EN] 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE SUBSTITUÉS EN 3,4 UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009135299A1

  公开（公告）日：2009-11-12

  The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position oxopyridine and having the formula (I). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.

  本发明涉及具有在4位氧吡啶基的3,4-取代哌啶基肾素抑制剂化合物，其化学式为(I)。该发明还涉及含有上述化合物的药物组合物，以及它们在治疗心血管事件和肾功能不全中的用途。
• Gonadotropin releasing hormone receptor antagonists
  申请人：Garrick Michael Lloyd

  公开号：US20060019965A1

  公开（公告）日：2006-01-26

  The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

  本发明涉及促性腺激素释放激素（“GnRH”）（也称为促黄体生成激素释放激素）受体拮抗剂。

表征谱图